Industry
Biotechnology
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Loading...
Open
26.40
Mkt cap
1.2B
Volume
1.6M
High
27.16
P/E Ratio
-8.95
52-wk high
42.20
Low
24.65
Div yield
N/A
52-wk low
8.79
Portfolio Pulse from Erica Kollmann
December 11, 2023 | 5:50 pm
Portfolio Pulse from Benzinga Newsdesk
November 07, 2023 | 2:09 pm
Portfolio Pulse from Benzinga Newsdesk
November 06, 2023 | 2:16 pm
Portfolio Pulse from Ryan Gustafson
October 25, 2023 | 7:43 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2023 | 6:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2023 | 1:17 pm
Portfolio Pulse from Benzinga Insights
October 24, 2023 | 5:35 pm
Portfolio Pulse from Lisa Levin
October 19, 2023 | 5:52 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.